Active Ingredient History
Sertraline (trade names Zoloft and others) is an antidepressant of the selective serotonin reuptake inhibitor (SSRI) class. Sertraline is primarily prescribed for major depressive disorder in adult outpatients as well as obsessive-compulsive disorder, panic disorder, and social anxiety disorder, in both adults and children. The exact mechanism of action sertraline is not fully known, but the drug appears to selectively inhibit the reuptake of serotonin at the presynaptic membrane. This results in an increased synaptic concentration of serotonin in the CNS, which leads to numerous functional changes associated with enhanced serotonergic neurotransmission. It is suggested that these modifications are responsible for the antidepressant action observed during long-term administration of antidepressants. It has also been hypothesized that obsessive-compulsive disorder is caused by the dysregulation of serotonin, as it is treated by sertraline, and the drug corrects this imbalance. Compared to other SSRIs, sertraline tends to be associated with a higher rate of psychiatric side effects and diarrhea. It tends to be more activating (that is, associated with a higher rate of anxiety, agitation, insomnia, etc.) than other SSRIs, aside from fluoxetine. Over a two-week treatment of healthy volunteers, sertraline slightly improved verbal fluency but did not affect word learning, short-term memory, vigilance, flicker fusion time, choice reaction time, memory span, or psychomotor coordination. In spite of lower subjective rating, that is, feeling that they performed worse, no clinically relevant differences were observed in the objective cognitive performance in a group of people treated for depression with sertraline for 1.5 years as compared to healthy controls NCATS
Drug Pricing (per unit)
Note: This drug pricing data is preliminary, incomplete, and may contain errors.
| Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
|---|
| Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
|---|
Obsessive-Compulsive Disorder (approved 1991)
Panic Disorder (approved 1991)
Phobic Disorders (approved 1991)
Premenstrual Dysphoric Disorder (approved 1991)
Stress Disorders, Post-Traumatic (approved 1991)
22q11 Deletion Syndrome (Phase 2)
Acute Coronary Syndrome (Phase 1/Phase 2)
Acute Pain (Phase 2)
Adolescent (Phase 2)
Affect (Phase 4)
Agoraphobia (Phase 4)
AIDS-Related Opportunistic Infections (Phase 3)
Alcoholism (Phase 4)
Alzheimer Disease (Phase 4)
Angina, Unstable (Phase 3)
Anxiety (Phase 4)
Anxiety Disorders (Phase 4)
Anxiety, Separation (Phase 3)
Asthma (Phase 4)
Autism Spectrum Disorder (Phase 2)
Autistic Disorder (Phase 3)
Bipolar Disorder (Phase 4)
Bone Diseases (Phase 3)
Brain Injuries, Traumatic (Phase 2/Phase 3)
Burning Mouth Syndrome (Phase 3)
Cardiovascular Diseases (Phase 3)
Chest Pain (Phase 4)
Cocaine-Related Disorders (Phase 2)
Coccidioidomycosis (Phase 2)
Cognition Disorders (Phase 4)
Compulsive Behavior (Phase 3)
Conversion Disorder (Phase 4)
Coronary Artery Disease (Phase 4)
Counseling (Phase 1/Phase 2)
Cryptococcosis (Phase 3)
Cryptococcus (Phase 3)
Dementia (Phase 4)
Depression (Phase 4)
Depression, Postpartum (Phase 4)
Depressive Disorder, Major (Phase 4)
Depressive Disorder, Treatment-Resistant (Phase 3)
Diabetes Mellitus (Phase 4)
Diabetes Mellitus, Type 2 (Phase 4)
Dissociative Disorders (Phase 4)
Dizziness (Phase 1)
Dysthymic Disorder (Phase 4)
Epilepsy (Phase 4)
Fragile X Syndrome (Phase 2)
Gambling (Phase 2)
General Surgery (Phase 3)
Glioblastoma (Phase 1)
Healthy Volunteers (Phase 4)
Heart Diseases (Phase 3)
Heart Failure (Phase 4)
Hepatitis C (Phase 2)
Hepatitis C, Chronic (Phase 1)
HIV Infections (Phase 4)
Huntington Disease (Phase 1)
Hypertension (Phase 4)
Intellectual Disability (Phase 3)
Kidney Failure, Chronic (Phase 3)
Leukemia, Myeloid, Acute (Phase 1)
Liver Cirrhosis, Biliary (Phase 2)
Meningitis, Cryptococcal (Phase 3)
Meningitis, Fungal (Phase 3)
Mental Disorders (Phase 4)
Migraine Disorders (Phase 1)
Mood Disorders (Phase 2/Phase 3)
Myelodysplastic Syndromes (Phase 1)
Myocardial Infarction (Phase 3)
Neoplasms (Phase 3)
Neurodevelopmental Disorders (Phase 2)
Neuroticism (Phase 4)
Obesity (Phase 1)
Obsessive Behavior (Phase 4)
Obsessive-Compulsive Disorder (Phase 4)
Orthostatic Intolerance (Phase 1/Phase 2)
Pain (Phase 4)
Panic Disorder (Phase 4)
Parkinson Disease (Phase 1/Phase 2)
Pediatrics (Phase 2)
Phobia, Social (Phase 4)
Pregnancy (Phase 4)
Premenstrual Dysphoric Disorder (Phase 4)
Premenstrual Syndrome (Phase 4)
Prostatic Neoplasms (Phase 2/Phase 3)
Pruritus (Phase 2)
Psychological Distress (Phase 4)
Psychophysiologic Disorders (Phase 3)
Schizophrenia (Phase 4)
Seizures (Phase 4)
Self-Injurious Behavior (Phase 3)
Sexual Dysfunction, Physiological (Phase 4)
Stereotyped Behavior (Phase 3)
Streptococcus (Phase 2)
Stress Disorders, Post-Traumatic (Phase 4)
Stress Disorders, Traumatic, Acute (Phase 4)
Stroke (Phase 4)
Substance-Related Disorders (Phase 2)
Suicide, Attempted (Phase 2/Phase 3)
Tachycardia (Phase 1/Phase 2)
Tic Disorders (Phase 2)
Tourette Syndrome (Phase 2)
Tuberculosis (Phase 4)
Tuberous Sclerosis (Phase 2)
| Trial | Phase | Start Date | Organizations | Indications |
|---|
Feedback
Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).
Report issue
